Rigontec: Merck boosts cancer pipeline in €464m deal
Merck & Co has announced it will acquire immunotherapy-focused Rigontec and lead candidate RGT100, designed to treat patients with solid tumours and lymphoma.
Read full article »
Rigontec develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases.
Read more